Veteran private equity investor with operational and deal experience across technology and software-enabled services. Craig McFadzean led growth-oriented investments, board-level value creation and strategic exits, focusing on scaling recurring-revenue business models and go-to-market expansion. Prior roles span operating leadership and principal investing at mid-market buyout and growth firms; adept at commercial due diligence, CEO partnering and M&A structuring. Education includes MBA and engineering background, providing analytical rigor to portfolio transformation initiatives.
Veteran private equity investor with operational and deal experience across technology and software-enabled services. Craig McFadzean led growth-oriented investments, board-level value creation and strategic exits, focusing on scaling recurring-revenue business models and go-to-market expansion. Prior roles span operating leadership and principal investing at mid-market buyout and growth firms; adept at commercial due diligence, CEO partnering and M&A structuring. Education includes MBA and engineering background, providing analytical rigor to portfolio transformation initiatives.
Combines operational rigor and growth-oriented private equity discipline to back software and services businesses with recurring revenue. Prefers scaling mid-market companies through go-to-market expansion, commercial diligence-led value creation, and CEO partnership. Capital allocation favors control or influential minority positions enabling product-led growth, customer success investment, and bolt-on M&A. Time horizon is multi-year, with disciplined risk management via unit-economics focus, staged value milestones, and exit planning tied to revenue quality and margin expansion.
Combines operational rigor and growth-oriented private equity discipline to back software and services businesses with recurring revenue. Prefers scaling mid-market companies through go-to-market expansion, commercial diligence-led value creation, and CEO partnership. Capital allocation favors control or influential minority positions enabling product-led growth, customer success investment, and bolt-on M&A. Time horizon is multi-year, with disciplined risk management via unit-economics focus, staged value milestones, and exit planning tied to revenue quality and margin expansion.
| Trades 323 | Longs Won 214/323 66% | Profit Factor 4.87 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $447,705.97 |
| Average Win $190,057.4 | Best Trade (Oct 14) $4.62M | Sharpe Ratio -9.75 |
| Average Loss -$76,667.25 | Worst Trade (Oct 15) -$1.64M | Z-Score 3.13 (99.82%) |
| Commissions $0 | Avg. Trade Length 10m 2w 6d | Expectancy $100,048.15 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 1,942 | 1,748 | 1,553 | 1,359 | 1,165 | 971 | 777 | 583 | 388 | 194 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 2,441 | $523,533.87 | $839,118.16 | - | $315,584.29 | 60.28% | +0.233% |
ABBV AbbVie Inc. | 800 | $201,312 | $230,808 | - | $29,496 | 14.65% | +1.774% |
AGG iShares Core U.S. Aggregate Bond ETF | 24,017 | $2.36M | $2.29M | - | -$72,090.26 | -3.05% | +0.585% |
AMZN Amazon.com Inc | 19,084 | $4.17M | $4.82M | - | $656,076.61 | 15.74% | -0.531% |
APO Apollo Global Management, Inc. | 11,452 | $1.74M | $1.29M | - | -$453,173.36 | -26.04% | -0.9% |
BABA Alibaba Group Holding Limited SP ADR | 34,759 | $4.32M | $3.82M | - | -$500,922.4 | -11.6% | -1.169% |
BIDU Baidu Inc. | 13,000 | $1.45M | $1.06M | - | -$386,225 | -26.67% | -0.226% |
BIIB Biogen Inc. | 12,068 | $2.53M | $2.88M | - | $350,239.52 | 13.83% | +2.603% |
BLK BlackRock, Inc. | 3,583 | $3.64M | $3.95M | - | $307,675.86 | 8.45% | +2.642% |
BMO Bank of Montreal | 11,300 | $1.11M | $1.87M | - | $754,553.9 | 67.73% | +1.07% |
BND Vanguard Total Bond Market Index Fund | 2,051 | $148,654.45 | $145,200.54 | - | -$3,453.91 | -2.32% | +0.561% |
BRK-B Berkshire Hathaway Inc. | 8,450 | $3.9M | $4.47M | - | $565,630.62 | 14.5% | +0.41% |
BSX Boston Scientific Corporation | 56,605 | $2.53M | $2.48M | - | -$50,860.58 | -2.01% | +2.058% |
CCJ Cameco Corporation | 39,110 | $1.84M | $3.23M | - | $1.39M | 75.63% | +1.362% |
CNQ Canadian Natural Resources Limited | 99,641 | $4.85M | $5.2M | - | $352,999.35 | 7.29% | +0.675% |
CRSP Crispr Therapeutics AG | 2,556 | $139,404 | $130,304.88 | - | -$9,099.12 | -6.53% | +1.513% |
DFAC Dimensional U.S. Core Equity 2 ETF | 2,322 | $103,004 | $104,501.61 | - | $1,497.61 | 1.45% | +0.267% |
EFA iShares MSCI EAFE ETF | 5,735 | $502,838.6 | $592,310.8 | - | $89,472.2 | 17.79% | +0.516% |
EWC iShares MSCI Canada ETF | 3,358 | $193,555 | $200,925.93 | - | $7,370.93 | 3.81% | +0.97% |
FXI iShares China Large-Cap ETF | 80,545 | $2.89M | $2.75M | - | -$142,417.26 | -4.92% | +0.812% |